Have a feature idea you'd love to see implemented?
Let us know!
CSTL Castle Biosciences Inc
Price (delayed)
$29.81
Market cap
$834.9M
P/E Ratio
135.5
Dividend/share
N/A
EPS
$0.22
Enterprise value
$766.68M
Castle Biosciences is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently
Highlights
The net income has surged by 108% year-on-year
CSTL's EPS has surged by 108% year-on-year
The debt has soared by 84% YoY and by 6% QoQ
Castle Biosciences's quick ratio has decreased by 3.9% QoQ
Key stats
What are the main financial stats of CSTL
Market
Valuations
Earnings
Shares outstanding
28.01M
Market cap
$834.9M
Enterprise value
$766.68M
Price to earnings (P/E)
135.5
Price to book (P/B)
1.87
Price to sales (P/S)
2.66
EV/EBIT
65.95
EV/EBITDA
30.57
EV/Sales
2.46
Revenue
$311.88M
EBIT
$11.63M
EBITDA
$25.08M
Free cash flow
$34.55M
Per share
Balance sheet
Liquidity
EPS
$0.22
Free cash flow per share
$1.24
Book value per share
$15.9
Revenue per share
$11.2
TBVPS
$14.51
Total assets
$514.57M
Total liabilities
$73.51M
Debt
$26.74M
Equity
$441.06M
Working capital
$300.48M
Debt to equity
0.06
Current ratio
7.78
Quick ratio
7.48
Net debt/EBITDA
-2.72
Margins
Efficiency
Dividend
EBITDA margin
8%
Gross margin
81.9%
Net margin
1.9%
Operating margin
-0.3%
Return on assets
1.3%
Return on equity
1.5%
Return on invested capital
4.5%
Return on capital employed
2.5%
Return on sales
3.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CSTL stock price
How has the Castle Biosciences stock price performed over time
Intraday
3.22%
1 week
6.09%
1 month
-7.59%
1 year
50.18%
YTD
38.14%
QTD
4.52%
Financial performance
How have Castle Biosciences's revenue and profit performed over time
Revenue
$311.88M
Gross profit
$255.43M
Operating income
-$1.04M
Net income
$6.08M
Gross margin
81.9%
Net margin
1.9%
The net income has surged by 108% year-on-year
The net margin has soared by 105% YoY
The operating income has soared by 99% YoY and by 93% from the previous quarter
The operating margin has surged by 99% year-on-year and by 95% since the previous quarter
Growth
What is Castle Biosciences's growth rate over time
Valuation
What is Castle Biosciences stock price valuation
P/E
135.5
P/B
1.87
P/S
2.66
EV/EBIT
65.95
EV/EBITDA
30.57
EV/Sales
2.46
CSTL's EPS has surged by 108% year-on-year
CSTL's price to book (P/B) is 36% lower than its 5-year quarterly average of 2.9 but 17% higher than its last 4 quarters average of 1.6
The equity is up by 14% year-on-year and by 4% since the previous quarter
The P/S is 71% below the 5-year quarterly average of 9.3 but 11% above the last 4 quarters average of 2.4
CSTL's revenue has soared by 62% YoY and by 8% from the previous quarter
Efficiency
How efficient is Castle Biosciences business performance
Castle Biosciences's return on invested capital has surged by 111% YoY
CSTL's return on sales has surged by 109% year-on-year
The ROE has soared by 108% YoY
Castle Biosciences's return on assets has surged by 107% YoY
Dividends
What is CSTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CSTL.
Financial health
How did Castle Biosciences financials performed over time
The total liabilities has grown by 46% year-on-year and by 16% since the previous quarter
Castle Biosciences's total assets has increased by 18% YoY and by 6% QoQ
The debt is 94% lower than the equity
The debt has soared by 84% YoY and by 6% QoQ
CSTL's debt to equity has surged by 50% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.